8-K: American Shared Hospital Services Reports Record Revenue Backlog Following Acquisition

American Shared Hospital Services announced a record projected revenue backlog of $210 million, more than doubling after acquiring Rhode Island Radiation Therapy Cancer Centers, alongside a 5.9% revenue increase in Q1 2024.

Summary

• American Shared Hospital Services reported a record projected revenue backlog of over $210 million as of May 10, 2024, which more than doubled due to the acquisition of a 60% stake in three Rhode Island Radiation Therapy Cancer Centers.
• The company's total revenue for the first quarter of 2024 was $5.2 million, a 5.9% increase compared to the same period in 2023.
• Proton beam radiation therapy revenue increased by 14.5%, while Gamma Knife revenue decreased slightly by 1.7% due to the expiration of two customer agreements.
• Gross margin for the quarter was $2.1 million, a 12.3% increase year-over-year, representing 41.1% of revenue.
• The company experienced an operating loss of $85,000 in Q1 2024, compared to an operating income of $98,000 in Q1 2023, primarily due to higher SG&A costs related to new business opportunities, including the Rhode Island acquisition.
• Adjusted EBITDA for the first quarter was $1,744,000, down from $1,903,000 in the same period last year, due to acquisition costs.
• Cash at the end of the quarter was $13.042 million, compared to $13.808 million at the end of 2023.
• The company signed one new order to upgrade an existing customer to a Leksell Gamma Knife Esprit.

Sentiment

Score: 6

Explanation: The document presents a mixed picture with strong revenue backlog and growth, but also a decrease in profitability and EBITDA. The acquisition is a positive move, but the associated costs have impacted the bottom line. The sentiment is cautiously optimistic.

Positives

• The company achieved a record projected revenue backlog of over $210 million.
• Total revenue increased by 5.9% year-over-year.
• Gross margin increased by 12.3% year-over-year.
• Proton beam radiation therapy revenue saw a significant increase of 14.5%.
• The company's balance sheet remains strong with $13.0 million in cash and equivalents.
• The company is expanding its business model into direct patient services in the U.S.
• The company signed four lease extensions over the last 12 months from its base of ten Gamma Knife sites.

Negatives

• The company experienced an operating loss of $85,000 in Q1 2024, compared to an operating income of $98,000 in Q1 2023.
• Adjusted EBITDA decreased to $1,744,000 from $1,903,000 in the same period last year.
• Gamma Knife revenue decreased slightly by 1.7% due to the expiration of two customer agreements.
• Proton beam radiation therapy fractions decreased by 16.9% due to normal, cyclical fluctuations.
• Cash decreased from $13.808 million at the end of 2023 to $13.042 million at the end of Q1 2024.

Risks

• The company's financial results may vary between quarters.
• Changes to CMS reimbursement rates or methodology could impact revenue.
• The timing, financing, and operations of the company's product lines carry risks.
• Expanding into new markets presents risks.
• The integration of acquired businesses could adversely affect financial results.
• Current and future acquisitions may negatively affect the company's financial position.

Future Outlook

The company is optimistic about future growth prospects, citing a strong sales pipeline, the expansion of its product portfolio, and the addition of new international and domestic centers. They are well positioned for future growth due to a strong balance sheet and consistent cash flow.

Management Comments

• Ray Stachowiak, CEO and Executive Chairman, stated that the company is extremely excited to report a record-breaking projected revenue backlog of over $210 million.
• Ray Stachowiak noted that Q1 2024 was another good quarter for AMS with continual improvement in operations and the sales team building solid momentum.
• Craig Tagawa, President and Chief Operating Officer, mentioned that the company continues to see momentum building with its enhanced sales team and expanded product portfolio.
• Craig Tagawa stated that the company's sales pipeline remains extremely strong and they are excited to announce additional projects as they come to fruition.

Industry Context

This announcement reflects a trend in the healthcare industry towards consolidation and expansion of specialized treatment centers. The acquisition of the Rhode Island centers allows American Shared Hospital Services to move into direct patient services, which is a growing area in the healthcare sector. The company's focus on advanced radiation therapy and radiosurgery aligns with the increasing demand for these technologies.

Comparison to Industry Standards

• The company's revenue growth of 5.9% is moderate compared to some high-growth healthcare technology companies, but it is solid considering the capital-intensive nature of their business.
• The gross margin of 41.1% is within the expected range for medical equipment leasing and services, but it is important to compare this to companies like Varian Medical Systems or Accuray, which are major players in the radiation therapy equipment market.
• The decrease in adjusted EBITDA is a concern and should be compared to the performance of similar companies in the medical equipment and services sector, such as Elekta or IBA.
• The company's move into direct patient services with the Rhode Island acquisition is similar to strategies employed by some larger healthcare providers, but it is a new direction for ASHS and will need to be monitored closely.

Stakeholder Impact

• Shareholders may be encouraged by the record revenue backlog and revenue growth, but concerned about the decrease in profitability and EBITDA.
• Employees may see opportunities for growth with the expansion of the company's operations.
• Customers will benefit from the company's expanded product portfolio and services.
• Suppliers may see increased demand for their products and services.
• Creditors may be reassured by the company's strong balance sheet and consistent cash flow.

Next Steps

• The company will continue to integrate the newly acquired Rhode Island Radiation Therapy Cancer Centers.
• The company will continue to expand its international operations, including the opening of the Puebla, Mexico center.
• The company will continue to pursue new business opportunities and lease extensions.
• The company will hold its Annual Meeting of Shareholders on June 25, 2024.

Key Dates

Keywords

revenue backlog, radiation therapy, Gamma Knife, proton beam, acquisition, EBITDA, medical equipment leasing, direct patient services, cancer treatment, healthcare